Leap Historical Balance Sheet

LPTX Stock

USD 0.45 0.06 15.85%

Trend analysis of Leap Therapeutics balance sheet accounts such as Total Stockholder Equity of 72.6 M provides information on Leap Therapeutics' total assets, liabilities, and equity, which is the actual value of Leap Therapeutics to its prevalent stockholders. By breaking down trends over time using Leap Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Leap Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Leap Therapeutics is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

About Leap Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Leap Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Leap Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Leap Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Leap currently owns. An asset can also be divided into two categories, current and non-current.

Leap Therapeutics Balance Sheet Chart

At this time, Leap Therapeutics' Other Current Assets are fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 555 M in 2025, whereas Total Assets are likely to drop slightly above 45.2 M in 2025.

Total Assets Total Current Liabilities Property Plant And Equipment Net Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Leap Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Leap Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Leap Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Leap Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Leap Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Leap Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Leap Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.At this time, Leap Therapeutics' Other Current Assets are fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 555 M in 2025, whereas Total Assets are likely to drop slightly above 45.2 M in 2025.

	2022	2023	2024	2025 (projected)
Cash	65.5M	70.6M	81.2M	85.3M
Accounts Payable	5.7M	6.5M	7.4M	7.8M

Cash Accounts Payable

Leap Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Other Assets	Property Plant Equipment	Short Term Debt
Total Assets		0.6	0.09	0.81	0.12	-0.92	-0.71	0.52	0.91	-0.29	-0.09	1.0	0.11	0.83	0.63	-0.32	0.37	0.75	0.42	0.27	1.0	0.3	0.71	0.15	0.05	-0.36
Other Current Liab	0.6		0.41	0.46	0.2	-0.61	-0.86	0.9	0.72	0.29	0.05	0.59	0.35	0.71	0.83	-0.56	0.04	0.88	0.73	0.38	0.59	0.05	0.66	0.54	0.47	-0.19
Total Current Liabilities	0.09	0.41		-0.43	-0.1	0.09	-0.36	0.49	0.12	0.34	0.51	0.06	0.82	0.15	0.26	0.13	-0.35	0.2	0.32	-0.03	0.08	-0.86	-0.22	0.69	0.03	0.76
Total Stockholder Equity	0.81	0.46	-0.43		0.24	-0.9	-0.57	0.37	0.81	-0.36	-0.29	0.83	-0.35	0.78	0.59	-0.44	0.45	0.71	0.24	0.34	0.82	0.76	0.81	-0.14	0.21	-0.79
Property Plant And Equipment Net	0.12	0.2	-0.1	0.24		-0.17	-0.26	0.23	0.11	0.6	0.16	0.12	-0.24	0.23	0.08	-0.28	0.07	0.26	0.01	0.95	0.11	0.28	0.25	0.23	0.62	-0.3
Net Debt	-0.92	-0.61	0.09	-0.9	-0.17		0.73	-0.56	-0.96	0.32	0.22	-0.93	0.03	-0.83	-0.67	0.53	-0.49	-0.8	-0.45	-0.29	-0.92	-0.49	-0.88	-0.04	-0.09	0.56
Retained Earnings	-0.71	-0.86	-0.36	-0.57	-0.26	0.73		-0.94	-0.81	-0.07	-0.3	-0.7	-0.26	-0.87	-0.89	0.49	0.1	-0.96	-0.67	-0.46	-0.7	-0.15	-0.62	-0.64	-0.48	0.29
Accounts Payable	0.52	0.9	0.49	0.37	0.23	-0.56	-0.94		0.69	0.21	0.32	0.5	0.38	0.74	0.87	-0.48	-0.13	0.9	0.7	0.41	0.51	0.0	0.54	0.68	0.55	-0.15
Cash	0.91	0.72	0.12	0.81	0.11	-0.96	-0.81	0.69		-0.27	-0.11	0.91	0.14	0.9	0.79	-0.48	0.4	0.87	0.48	0.25	0.91	0.29	0.82	0.18	0.14	-0.38
Non Current Assets Total	-0.29	0.29	0.34	-0.36	0.6	0.32	-0.07	0.21	-0.27		0.26	-0.32	0.22	-0.15	-0.08	-0.24	-0.21	0.01	0.13	0.54	-0.31	-0.28	-0.08	0.47	0.43	0.23
Non Currrent Assets Other	-0.09	0.05	0.51	-0.29	0.16	0.22	-0.3	0.32	-0.11	0.26		-0.1	0.45	0.1	0.08	0.28	-0.75	0.11	0.16	0.16	-0.09	-0.41	-0.48	0.78	0.17	0.33
Cash And Short Term Investments	1.0	0.59	0.06	0.83	0.12	-0.93	-0.7	0.5	0.91	-0.32	-0.1		0.08	0.83	0.63	-0.32	0.37	0.74	0.41	0.26	1.0	0.32	0.71	0.13	0.04	-0.38
Net Receivables	0.11	0.35	0.82	-0.35	-0.24	0.03	-0.26	0.38	0.14	0.22	0.45	0.08		0.08	0.13	0.13	-0.19	0.11	0.44	-0.24	0.11	-0.72	-0.17	0.49	-0.13	0.63
Common Stock Total Equity	0.83	0.71	0.15	0.78	0.23	-0.83	-0.87	0.74	0.9	-0.15	0.1	0.83	0.08		0.9	-0.34	0.13	0.93	0.35	0.4	0.83	0.28	0.66	0.31	0.41	-0.35
Common Stock Shares Outstanding	0.63	0.83	0.26	0.59	0.08	-0.67	-0.89	0.87	0.79	-0.08	0.08	0.63	0.13	0.9		-0.42	-0.02	0.94	0.5	0.31	0.63	0.18	0.62	0.41	0.54	-0.28
Non Current Liabilities Total	-0.32	-0.56	0.13	-0.44	-0.28	0.53	0.49	-0.48	-0.48	-0.24	0.28	-0.32	0.13	-0.34	-0.42		-0.4	-0.53	-0.6	-0.36	-0.31	-0.45	-0.76	-0.14	-0.27	0.54
Other Current Assets	0.37	0.04	-0.35	0.45	0.07	-0.49	0.1	-0.13	0.4	-0.21	-0.75	0.37	-0.19	0.13	-0.02	-0.4		0.05	-0.08	0.02	0.37	0.35	0.59	-0.67	-0.16	-0.3
Other Stockholder Equity	0.75	0.88	0.2	0.71	0.26	-0.8	-0.96	0.9	0.87	0.01	0.11	0.74	0.11	0.93	0.94	-0.53	0.05		0.59	0.45	0.74	0.3	0.74	0.47	0.5	-0.42
Total Liab	0.42	0.73	0.32	0.24	0.01	-0.45	-0.67	0.7	0.48	0.13	0.16	0.41	0.44	0.35	0.5	-0.6	-0.08	0.59		0.16	0.42	0.09	0.49	0.56	0.2	-0.25
Property Plant And Equipment Gross	0.27	0.38	-0.03	0.34	0.95	-0.29	-0.46	0.41	0.25	0.54	0.16	0.26	-0.24	0.4	0.31	-0.36	0.02	0.45	0.16		0.25	0.31	0.36	0.33	0.74	-0.36
Total Current Assets	1.0	0.59	0.08	0.82	0.11	-0.92	-0.7	0.51	0.91	-0.31	-0.09	1.0	0.11	0.83	0.63	-0.31	0.37	0.74	0.42	0.25		0.3	0.7	0.13	0.04	-0.36
Common Stock	0.3	0.05	-0.86	0.76	0.28	-0.49	-0.15	0.0	0.29	-0.28	-0.41	0.32	-0.72	0.28	0.18	-0.45	0.35	0.3	0.09	0.31	0.3		0.59	-0.37	0.24	-0.98
Net Tangible Assets	0.71	0.66	-0.22	0.81	0.25	-0.88	-0.62	0.54	0.82	-0.08	-0.48	0.71	-0.17	0.66	0.62	-0.76	0.59	0.74	0.49	0.36	0.7	0.59		-0.05	0.22	-0.67
Other Assets	0.15	0.54	0.69	-0.14	0.23	-0.04	-0.64	0.68	0.18	0.47	0.78	0.13	0.49	0.31	0.41	-0.14	-0.67	0.47	0.56	0.33	0.13	-0.37	-0.05		0.3	0.22
Property Plant Equipment	0.05	0.47	0.03	0.21	0.62	-0.09	-0.48	0.55	0.14	0.43	0.17	0.04	-0.13	0.41	0.54	-0.27	-0.16	0.5	0.2	0.74	0.04	0.24	0.22	0.3		-0.29
Short Term Debt	-0.36	-0.19	0.76	-0.79	-0.3	0.56	0.29	-0.15	-0.38	0.23	0.33	-0.38	0.63	-0.35	-0.28	0.54	-0.3	-0.42	-0.25	-0.36	-0.36	-0.98	-0.67	0.22	-0.29

Click cells to compare fundamentals

Leap Therapeutics Account Relationship Matchups

Leap Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	54.4M	117.9M	70.4M	72.8M	83.7M	45.2M
Other Current Liab	3.0M	4.9M	4.7M	6.0M	6.9M	7.2M
Total Current Liabilities	7.4M	10.0M	11.2M	12.7M	14.6M	9.7M
Total Stockholder Equity	46.7M	107.9M	58.9M	60.1M	69.2M	72.6M
Property Plant And Equipment Net	593K	495K	689K	262K	301.3K	444.1K
Net Debt	(51.5M)	(114.4M)	(64.8M)	(70.4M)	(63.3M)	(60.2M)
Retained Earnings	(223.0M)	(263.6M)	(318.2M)	(399.6M)	(359.6M)	(341.6M)
Accounts Payable	2.7M	4.2M	5.7M	6.5M	7.4M	7.8M
Cash	52.1M	114.9M	65.5M	70.6M	81.2M	85.3M
Non Current Assets Total	2.1M	1.0M	2.4M	1.2M	1.4M	1.9M
Non Currrent Assets Other	1.3M	383K	1.7M	966K	1.1M	1.3M
Cash And Short Term Investments	52.1M	114.9M	65.5M	70.6M	81.2M	42.0M
Net Receivables	73K	1.2M	2.1M	771K	886.7K	1.0M
Common Stock Total Equity	15K	24K	60K	88K	101.2K	106.3K
Common Stock Shares Outstanding	5.9M	8.6M	11.3M	20.4M	23.5M	24.7M
Liabilities And Stockholders Equity	54.4M	117.9M	70.4M	72.8M	83.7M	45.2M
Non Current Liabilities Total	3.4M	711K	348K	37K	262K	0.0
Other Current Assets	130K	769K	351K	183K	210.5K	284.3K
Other Stockholder Equity	270.2M	371.6M	376.8M	459.6M	528.5M	555.0M
Total Liab	7.7M	10.0M	11.5M	12.7M	14.6M	8.8M
Property Plant And Equipment Gross	593K	495K	689K	483K	555.5K	464.4K
Total Current Assets	52.3M	116.9M	68.0M	71.6M	82.3M	43.3M
Accumulated Other Comprehensive Income	(579K)	(267K)	128K	106K	95.4K	90.6K
Common Stock	60K	88K	99K	26K	29.9K	31.4K
Net Tangible Assets	(1.7M)	46.7M	107.9M	58.9M	67.7M	71.1M
Other Assets	2.1M	2.0M	542K	1.7M	2.0M	1.5M
Property Plant Equipment	1.2M	65K	36K	689K	792.4K	832.0K
Short Term Debt	816K	864K	832K	262K	235.8K	224.0K
Short Long Term Debt Total	552K	469K	678K	262K	235.8K	224.0K
Capital Surpluse	162.4M	193.3M	270.2M	371.6M	427.4M	448.8M
Deferred Long Term Liab	162K	831K	345K	576K	518.4K	442.1K
Non Current Liabilities Other	3.4M	159K	348K	37K	33.3K	31.6K
Retained Earnings Total Equity	(153.5M)	(195.2M)	(223.0M)	(263.6M)	(237.2M)	(249.1M)
Net Invested Capital	46.7M	107.9M	58.9M	60.1M	69.2M	45.9M
Net Working Capital	44.9M	106.9M	56.7M	58.9M	67.7M	46.5M
Capital Stock	60K	88K	99K	26K	29.9K	57.2K
Capital Lease Obligations	552K	469K	678K	262K	235.8K	224.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Leap Historical Balance Sheet

About Leap Balance Sheet Analysis

Leap Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accounts Payable

Leap Therapeutics balance sheet Correlations

Leap Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Leap Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Leap Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.95	Property Plant And Equipment Net
Other Stockholder Equity	+ 0.94	Common Stock Shares Outstanding
Other Stockholder Equity	+ 0.93	Common Stock Total Equity

Short Term Debt	- 0.98	Common Stock
Other Stockholder Equity	- 0.96	Retained Earnings
Cash	- 0.96	Net Debt
Accounts Payable	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.93	Net Debt
Total Current Assets	- 0.92	Net Debt